



Dear Banking, Commerce, and Insurance Committee,

Nebraska Cures has been a leading advocate for health science research for over 20 years. We support policies rooted in science and strive to advance the quality of life and economy for Nebraskans. In alliance with our mission, we strive to educate policymakers on medical research and health related public policy.

I am writing to express our support for LB 253, which seeks to provide insurance and medicaid coverage for biomarker testing. We believe that having access to biomarker testing is essential to keep Nebraskans healthy.

Biomarker testing is vital to the early detection, diagnosis, and treatment of many different diseases. As medical research is increasing the number of treatments available. It is important for medical professionals to use biomarkers to determine the best treatment plan for their patients.

Biomarker testing is also very cost-effective for both patients and insurance companies. While the upfront cost for the test can be quite expensive, it allows for the patient to receive specific care and not have to go through unnecessary treatment, which is more cost-effective in the long run.

We urge the legislator to consider the great impacts for patients and providers that LB 253 could have on disease treatment and to support this bill. We believe that biomarker testing is revolutionizing healthcare by offering more precise, personalized, and efficient medical care and that everyone should have access to this testing. Thank you for your consideration.

Sincerely,

A handwritten signature in black ink that reads "Amanda McGill Johnson". The signature is written in a cursive, flowing style.

Amanda McGill Johnson

Nebraska Cures Executive Director